TIDMTIME 
 
 
Timestrip PLC 
01 April 2009 
 
TIME.L 
Timestrip plc 
(the "Company") 
 
 
New Product Launch and NHS order 
 
 
The Company is pleased to announce the launch of a new product range - 
TimestripMedical - targeting healthcare providers with a number of different 
time and temperature based solutions to existing problems and issues in the 
healthcare environment. 
 
 
The first product in the range, TimestripIV, has been designed to help hospitals 
comply with existing policy directives that stipulate the need to change 
Peripheral Intravenous Cannulae (PVCs) every 72 hours. Up to 60% of cases of 
blood infections known as MRSA Bacteraemia are caused by PVC's and the cost of 
treating MRSA is estimated at GBP1 billion per annum, according to the National 
Audit Office. 
 
 
The Company is delighted to announce that it has received high levels of 
interest for this product from the UK's National Health Service, culminating in 
today's launch of a six months detailed assessment of TimestripIV by the 
Whittington Hospital in London. 
 
 
The Whittington has placed an order to purchase sufficient quantities of 
TimestripIV products to enable it to use TimestripIV in conjunction with PVCs 
that are used in the Hospital over the next six months. The Whittington has also 
undertaken to produce and publish studies and surveys involving practitioners 
and patients to evaluate the effectiveness of TimestripIV within the Hospital's 
infection control policy. 
 
 
Paul Freedman, Joint CEO Timestrip Plc: " We are delighted to announce this 
significant move into the healthcare market. TimestripIV can play an important 
role in the infection control policies of hospitals, helping to increase patient 
safety in a truly cost effective way. MRSA Bacteraemia is a global issue and we 
are delighted to have started working with the NHS on a product line that we 
believe has worldwide relevance. Other products in the TimestripMedical range 
will be announced in due course." 
 
 
 
 
Deborah Wheeler, Director of Nursing & Clinical Development Whittington Hospital 
NHS Trust: "We are very impressed by the potential of TimestripIV to assist in 
the monitoring of compliance with IV peripheral line replacement and see it as 
an important innovation for the Whittington to be introducing for the first time 
in the NHS. The Whittington places a high priority on patient protection and 
satisfaction and we believe that TimestripIV represents a unique opportunity to 
involve patients in their own care and increase confidence in the infection 
control policies that we have in place." 
 
 
For more information please contact: 
Paul Freedman, Joint CEO, Timestrip Plc 
01462 440700 
Geoff Nash, FinnCap, NOMAD                                                020 
7600 1658 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAEFLFXKXBEBBV
Time Finance (LSE:TIME)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Time Finance Charts.
Time Finance (LSE:TIME)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Time Finance Charts.